Editorial: Therapy-induced metastasis

Martin, Olga A.; Anderson, Robin L.

doi:10.1007/s10585-018-9914-x

Cited by 10 publications

(6 citation statements)

References 22 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of recent preclinical and clinical observations indicate an unexpected involvement of all major cancer treatment modalities in enhancing the number of circulating tumor cells, and as such, potentially inducing distant metastasis (1). With an ever increasing understanding of the molecular complexities and the intertwining circuitries governing the effect of tumor microenvironment on disease progression, it is not surprising that research efforts have focused on uncovering the mechanisms of therapy-driven tumor progression, which may obfuscate the longterm benefits of anticancer therapeutic interventions (2). Therapeutic procedures previously linked to paradoxical promotion of the prometastatic machinery include chemotherapy (3)(4)(5), radiotherapy (6)(7)(8), surgery (9), or even perioperative anesthesia (10).…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions

2019

View full text Add to dashboard Cite

Chemotherapy offers long-term clinical benefits to many patients with advanced cancer. However, recent evidence has linked the cytotoxic effects of chemotherapy with the de novo elicitation of a prometastatic tumor microenvironment. This "modified" tumor microenvironment is triggered by a chemotherapy-driven cytokine storm or through direct effects of certain chemotherapeutics on stromal and/or immune cells, the most critical being tumor-associated macrophages. These chemotherapy-educated cells act as facilitators in tumor-host cell interactions promoting the establishment of distant metastasis. Certain clinical studies now offer substantial evidence that prometastatic changes are indeed identified in the tumor microenvironment of certain patient subpopulations, especially those that do not present with any pathologic response after neoadjuvant chemotherapy. Deciphering the exact contextual prerequisites for chemotherapy-driven metastasis will be paramount for designing novel mechanism-based treatments for circumventing chemotherapy-induced metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions

2019

View full text Add to dashboard Cite

show abstract

“…In a study of 413 patients with brain metastasis of different causes, Amelot et al27 found that anticancer drugs, especially paclitaxel and its derivatives, promoted brain metastasis and reduce disease-free survival of patients. A recent review suggested that all commonly used treatments, including radiotherapy, chemotherapy, fine-needle puncture, and surgery, can cause an increase in circulating tumor cells and promote cancer progression and distant metastasis 28. Thus, the positive effects of hydrogen inhalation on cancer patients are very encouraging.…”

Section: Discussionmentioning

confidence: 99%

“Real world survey” of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients

Chen

Kong

Lv³

et al. 2019

Med Gas Res

View full text Add to dashboard Cite

Advanced cancer treatment is a huge challenge and new ideas and strategies are required. Hydrogen exerts antioxidant and anti-inflammatory effects that may be exploited to control cancer, the occurrence and progression of which is closely related to peroxidation and inflammation. We conducted a prospective follow-up study of 82 patients with stage III and IV cancer treated with hydrogen inhalation using the "real world evidence" method. After 3-46 months of follow-up, 12 patients died in stage IV. After 4 weeks of hydrogen inhalation, patients reported significant improvements in fatigue, insomnia, anorexia and pain. Furthermore, 41.5% of patients had improved physical status, with the best effect achieved in lung cancer patients and the poorest in patients with pancreatic and gynecologic cancers. Of the 58 cases with one or more abnormal tumor markers elevated, the markers were decreased at 13-45 days (median 23 days) after hydrogen inhalation in 36.2%. The greatest marker decrease was in achieved lung cancer and the lowest in pancreatic and hepatic malignancies. Of the 80 cases with tumors visible in imaging, the total disease control rate was 57.5%, with complete and partial remission appearing at 21-80 days (median 55 days) after hydrogen inhalation. The disease control rate was significantly higher in stage III patients than in stage IV patients (83.0% and 47.7%, respectively), with the lowest disease control rate in pancreatic cancer patients. No hematological toxicity was observed although minor adverse reactions that resolved spontaneously were seen in individual cases. In patients with advanced cancer, inhaled hydrogen can improve patients' quality-of-life and control cancer progression. Hydrogen inhalation is a simple, low-cost treatment with few adverse reactions that warrants further investigation as a strategy for clinical rehabilitation of patients with advanced cancer. The study protocol received ethical approval from the Ethics Committee of

show abstract

“…Once a hotly debated topic, concerns that cancer treatments could promote its spread have been largely overshadowed by advances in cancer survival. However, now, as cure is becoming a realisable goal for a greater proportion of patients, the extent to which therapies promote cancer is being revisited [1]. Of the many factors at play in therapeutic management, malignant cells shed from primary tumours due to resective procedures are an obvious cause for concern [2].…”

Section: Introductionmentioning

confidence: 99%

The Impact of Surgery on Circulating Malignant Tumour Cells in Oral Squamous Cell Carcinoma

Curtin

Thomson

Wong

et al. 2023

Cancers

View full text Add to dashboard Cite

Importance: The extent to which surgical management of oral squamous cell carcinoma (OSCC) disseminates cancer is currently unknown. Objective: To determine changes in numbers of malignant cells released into systemic circulation immediately following tumour removal and over the first seven post-operative days. Design: An observational study from March 2019 to February 2021. Setting: This study was undertaken at Queen Mary University Hospital, Hong Kong. Participants: Patients with biopsy-proven oral SCC were considered for eligibility. Patients under 18 years of age, pregnant or lactating women and those unable to understand the study details or unable to sign the consent form were excluded. Twenty-two patients were enrolled (12 male and 10 female) with mean age of 65.5 years. Intervention: Primary tumour management was performed in accord with multi-disciplinary team agreement. Anaesthesia and post-operative care were unaltered and provided in accord with accepted clinical practice. Main Outcomes and Measures: Three types of malignant cells detected in peripheral blood samples were enumerated and sub-typed based on the presence of chromosomal aneuploidy and immunohistochemical characteristics. To test the hypothesis that malignant cells are released by surgery, the numbers of single circulating tumour cells (CTCs), circulating tumour microemboli (CTM) and circulating endothelial cells (CTECs) were recorded pre-operatively, upon tumour removal and the second and seventh post-operative days. Results: Of a potential 88 data collection points, specimens were not obtainable in 12 instances. Tumour removal resulted in a statistically significant increase in CTCs and a non-statistically significant rise in CTMs. CTCs, CTMs and CTECs were detected in the majority of patients up to the seventh post-operative day. Individual patients demonstrated striking increases in post-operative CTCs and CTECs numbers. Conclusions/Relevance: Surgical management of OSCC has a significant impact on the systemic distribution of cancer cells. Malignant cells persisted post-operatively in a manner independent of recognised staging methods suggesting differences in tumour biology between individuals. Further investigation is warranted to determine whether circulating malignant cell enumeration can be used to refine risk stratification for patients with OSCC.

show abstract

Editorial: Therapy-induced metastasis

Cited by 10 publications

References 22 publications

Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions

Chemotherapy-Induced Metastasis: Molecular Mechanisms, Clinical Manifestations, Therapeutic Interventions

“Real world survey” of hydrogen-controlled cancer: a follow-up report of 82 advanced cancer patients

The Impact of Surgery on Circulating Malignant Tumour Cells in Oral Squamous Cell Carcinoma

Contact Info

Product

Resources

About